MYOS Appoints Glen R. Fleischer as CEO

Published: Jan 03, 2013

CEDAR KNOLLS, NJ--(Marketwire - January 03, 2013) -

Highlighted Links

MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS"), announced today the appointment of Glen R. Fleischer as its Chief Executive Officer.

Mr. Fleischer has extensive experience in building strong, profitable, sustained growth consumer brands. He has led consumer healthcare, food and disposable product businesses, all driven by product innovation, technological excellence and highly effective consumer engagement. He served in key leadership roles over sixteen years at Kraft Foods and led marketing for Bayer's U.S. consumer healthcare business. Most recently, Mr. Fleischer served as president of the Pet Division at Central Garden and Pet. Mr. Fleischer's leadership success began at Kimberly-Clark Corporation, where he led the venture team that created the children's disposable training pants category -- a business which now approximates a billion dollars in annual global revenue. He began his career at The Procter & Gamble Company, and earned his MBA with Distinction at NYU's Stern School of Business.

"We are thrilled to have Glen Fleischer join MYOS as our CEO," said Robert J. Hariri, M.D., Ph.D., and Acting Chairman of the Board of MYOS Corporation. "I believe Glen's leadership experience and business acumen, including his successful track record as an executive and business leader, make him a perfect choice as we grow our business." Mr. Fleischer added, "There is a significant unmet need in human muscle health and I believe MYOS's singular focus, innovative efforts, and world class talent can make a significant impact in addressing this need over the years to come. I look forward to leading the company and to positioning it for sustainable future growth."

Additional information regarding this appointment will be available in a Current Report on Form 8-K to be filed by MYOS with the Securities and Exchange Commission.

About MYOS Corporation

MYOS is a development stage company focused on the discovery, development and commercialization of products that improve human muscle health and performance. MYOS is the owner of MYO-T12, the world's first clinically demonstrated Myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. MYO-T12 is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards of physical health and wellness enhancement. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.

Forward-Looking Statements

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the rollout of MYO-X in GNC stores, the successful rollout of MYO-X at Vitamin Shoppe, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.